The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at an assay dependent dilution. Antibody detection limit dilution: 1/64000.
WB: Use at a concentration of 0.1 - 0.3 µg/ml. Predicted molecular weight: 78 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Direct ligand for the ERBB4 tyrosine kinase receptor. Binding results in ligand-stimulated tyrosine phosphorylation and activation of the receptor. Does not bind to the EGF receptor, ERBB2 or ERBB3 receptors. May be a survival factor for oligodendrocytes.
Highly expressed in most regions of the brain with the exception of corpus callosum. Expressed at lower level in testis. Not detected in heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, ovary, small intestine, colon and peripheral blood leukocytes.
Belongs to the neuregulin family. Contains 1 EGF-like domain.
Isoform 3 is expressed in fetal brain but not in other fetal tissues.
The cytoplasmic domain may be involved in the regulation of trafficking and proteolytic processing. Regulation of the proteolytic processing involves initial intracellular domain dimerization. ERBB receptor binding is elicited entirely by the EGF-like domain.
Proteolytic cleavage close to the plasma membrane on the external face leads to the release of the soluble growth factor form. Extensive glycosylation precedes the proteolytic cleavage (By similarity). Isoform 3 is glycosylated.
Secreted; Cell membrane. Does not seem to be active and Cell membrane. Isoform 3 is also proteolytically released as a soluble form.